InsidersTradesSigma
AN2 Therapeutics, Inc.: insider trades · United States · SEC (Form 4)
SEC:an2-therapeutics-inc-f307a0US·SEC (Form 4)Mcap 162M€Healthcare
Discover the full directors' dealings record of AN2 Therapeutics, Inc., a listed equity based in United States. Shares trade on US US, under the supervision of SEC (Form 4). Operating in the Healthcare sector, AN2 Therapeutics, Inc. has logged 11 insider filings. Market capitalisation: €161.7m. The latest transaction was reported on 24 June 2022 (C). Among the most active insiders: Adjuvant Global Health Technology Fund, L.P.. All data is accessible without an account.
11
Insider Decl.
0
Thresholds
€153,993
2 ops.
Buy Volume
·
0 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
4.49 €
Analyst consensus
1 analystsStrong buy
9.00 €Target 9.00 €(+100%)9.00 €
Income statement
Net income−35.2 M€0.0% margin
Valuation
PER (forward)-4.3x
P/Book2.3x
Balance sheet & cash
Market cap161.7 M€
Free Cash Flow−29.8 M€
Profitability & ownership
ROE-44.6%
ROA-27.5%
% insiders18.9%
% institutions69.0%
Last declaration on 24 June 2022
Declarations11 total
Executives●C5SEC
1,651,636 shares
Common Stock
SEC:0000899243-22-024034:0·
Executives●J30SEC
€371,94826,511 shares@ €14.02990.23% mcap100.0% of flow
Common Stock
SEC:0000899243-22-024054:0·
Executives●J21SEC
€371,94826,511 shares@ €14.02990.23% mcap100.0% of flow
Common Stock
SEC:0000899243-22-024050:0·
Executives▲Purchase9SEC
€2,291302 shares@ €7.58590.0014% mcap1.5% of flow
Common Stock
SEC:0001104659-22-073920:0·
Ideal exit: 18 Mar 2023 (T+270)
Executives▲Purchase23SEC
€151,70220,000 shares@ €7.58510.094% mcap98.5% of flow
Common Stock
SEC:0001104659-22-071465:0·
Ideal exit: 10 Mar 2023 (T+270)
Executives●C25SEC
4,907 shares
Common Stock
SEC:0000899243-22-012989:0·
Executives●C5SEC
1,651,636 shares
Common Stock
SEC:0000899243-22-012990:0·
11 of 11 declarations